Yourlocation: Home > News > Chenodeoxycholic acid for the treatment of gallstones
Chenodeoxycholic acid(CDCA) has a certain pharmacological effect, and has a certain toxicity, the pharmacological studies of CDCA mainly concentrated in the role of cholesterol-containing gallstones, its molecular level in the research and mechanism of action has also been reported. Combined taurine deoxycholic acid(TCDCA) also has a certain pharmacological effects, but is mainly used as a valuable chemical reagents. Although CDCA and TCDCA have certain application value, they have not been paid much attention because of the complexity of extraction and lack of detailed research.
Clinical use of chenodeoxycholic acid for the treatment of gallstones, cholesterol gallstones have a good dissolution. Mainly used for the treatment of hepatobiliary disease, antitussive, asthma and so on. CDCA can inhibit the activity of HMG-CoA reductase, stimulate the activity of cholic acid synthesis rate limiting enzyme, thereby expanding the bile acid to facilitate the dissolution of cholesterol in the micelle state. CDCA can also inhibit liver excretion of cholesterol, negative feedback mechanism to reduce cholesterol synthesis, but also reduce the small intestine on the reabsorption of cholesterol. Studies have confirmed that chenodeoxycholic acid can affect cholesterol synthesis, reduce liver cells to produce cholesterol, the bile cholesterol and cholic acid ratio is moderate, and have a strong role in gallbladder; a significant antibacterial effect.

Address:A3 Building, Dongli Aviation Business District,No.8,Pingying Road, Dongli District, Tianjin, P.R.China, 300300 Tel:+86-022-58602231 Fax:+86-022-58602232
Copyright © Tianjin NWS Biotechnology and Medicine Co. Ltd.